Everolimus-eluting stents: update on current clinical studies

olimus-eluting stents: update on current clinical studies Review (5266) Total Article Views Authors: Allocco DJ, Joshi AA, Dawkins KD Video abstract presented by Dominic Allocco Views: 569 Published Date July 2011 Volume 2011:4 Pages 91 - 98 DOI: http://dx.doi.org/10.2147/MDER.S22043 Dominic J Allocco, Anita A Joshi, Keith D Dawkins Boston Scientific Corporation, Natick, MA, USA Abstract: Everolimus-eluting stents (EES) have become the most commonly implanted coronary stents worldwide. This review describes and analyzes the clinical data supporting the use of EES, focusing primarily on published, randomized, controlled trials. Everolimuseluting stents have been shown to have less restenosis, stent thrombosis, and periprocedural myocardial infarction compared with earlier generation paclitaxel-eluting stents (PES). Lower rates of adverse events for EES compared with PES were generally seen in all subgroups, with the notable exception of patients with diabetes mellitus. There have been fewer, randomized, clinical trials comparing EES with either sirolimus-eluting stents or zotarolimus-eluting stents, although very good results with EES have been observed in the trials that have been performed. Recent clinical trial data suggest that this excellent safety and efficacy profile is maintained in a next-generation EES designed to have improved mechanical properties and radiopacity.